


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on September 8, 2006.

INFORMATION DISCLOSURE
STATEMENT
Patent Application
Docket No. ARS-102
Serial No. 10/510,015


Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Claudio Soto-Jara, Claudia Pena-Rossi
Serial No. : 10/510,015
Filed : September 30, 2004
Conf. No. : 4494
For : Novel OX40R Binding Agents

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98


Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of cited references.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/510,015	
			Filing Date	September 30, 2004	
			First Named Inventor	Claudio Soto-Jara	
			Art Unit		
			Examiner Name		
Sheet	1	of	2	Attorney Docket Number	ARS-102

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1	WO 01/72771 CD-ROM	10-04-2001	DGI Biotechnologies, L.L.C.	All	
	F2	WO 00/058494 CD-ROM	10-05-2000	Human Genome Sciences, Inc.	All	
	F3	WO 01/57274 CD-ROM	08-09-2001	Molecular Dynamics, Inc.	All	
	F4	WO 95/21915 CD-ROM	08-17-1995	The Board of Trustees of the Leland Stanford Junior University	All	
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/510,015	
			Filing Date	September 30, 2004	
			First Named Inventor	Claudio Soto-Jara	
			Group Art Unit		
			Examiner Name		
Sheet	2	of	2	Attorney Docket Number	ARS-102

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	ALIGNNET, J. <i>et al.</i> "Sequence of Staphylococcal Plasmid Gene, <i>vga</i> , Encoding a Putative ATP-binding Protein Involved in Resistance to Virginiamycin A-like Antibiotics" <i>Gene</i> , 1992, pp. 45-51, Vol. 117.	
	R2	BODMER, J. <i>et al.</i> "The Molecular Architecture of the TNF Superfamily" <i>TRENDS in Biochemical Sciences</i> , January 2002, pp. 19-26, Vol. 27, No. 1.	
	R3	STÜBER, E. <i>et al.</i> "The T Cell-B Cell Interaction via OX40-OX40L Is Necessary for the T Cell-Dependent Humoral Immune Response" <i>The Journal of Experimental Medicine</i> , March 1996, pp. 979-989, Vol. 183.	
	R4	WEINBERG, A. D. "OX40: Targeted Immunotherapy-Implications for Tempering Autoimmunity and Enhancing Vaccines" <i>TRENDS in Immunology</i> , February 2002, pp. 102-109, Vol. 23, No. 2.	
	R5	PENN, S. G. <i>et al.</i> "Protein #5114 Encoded by Probe for Measuring Heart Cell Gene Expression" Database accession no. ABB23115, XP002211957, January 23, 2002, Database GSP 'Online!	
	R6	ROSEN, C. A. <i>et al.</i> "Human Secreted Protein Sequence Encoded by Gene 39 SEQ ID NO: 99" Database accession no. AAB44733, XP002211958, February 12, 2001, Database GSP 'Online!	
	R7	BEASLEY, J. <i>et al.</i> "Insulin/Insulin-like Growth Factor Receptor-Binding Peptide #1955" Database accession no. AAU89999, XP002211956, June 18, 2002, Database GSP 'Online!	
	R8	ISONO, T. <i>et al.</i> "Expression of OX40 and OX40 Ligand Genes in Rabbit HTLV-I-Transformed T Cell Lines" Database accession no. 002765, XP002211959, December 15, 1998, Database SWALL 'Online!	
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.